This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients

This study has been terminated.
(not enough patients enrolled)
Information provided by (Responsible Party):
Gerhard Rogler, University of Zurich Identifier:
First received: November 11, 2009
Last updated: December 3, 2014
Last verified: December 2014

The investigators will study the effect of Adalimumab on the bone microstructure.

  • Trial with medicinal product

Condition Intervention Phase
Crohn's Disease Drug: Application of Adalimumab Phase 2

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Gerhard Rogler, University of Zurich:

Enrollment: 34
Study Start Date: August 2009
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Application of Adalimumab
    Adalimumab will be applied according to manufacture's instruction and official guidelines.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients cohort of the University Hospital Zurich

Inclusion criteria:

  • CDAI > 220 und < 450
  • Biologika naiv
  • CD seit > 6 Monaten

Exclusion criteria:

  • other TNF-Blocker
  • Steroids > 40 mg
  • Malignoma in der Anamnesis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01012570

Zurich, Switzerland
Sponsors and Collaborators
Gerhard Rogler
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
  More Information

Responsible Party: Gerhard Rogler, Prof.Dr.Dr. gerhard Rogler, University of Zurich Identifier: NCT01012570     History of Changes
Other Study ID Numbers: HUM-07-019
Study First Received: November 11, 2009
Last Updated: December 3, 2014

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases
Anti-Inflammatory Agents
Antirheumatic Agents processed this record on June 23, 2017